Diagnosi, protesi, vaccini, genomica: la medicina che guadagna anni di vita.
La medicina che guadagna anni di vita: screening assistiti dall’IA che esaminano milioni di pazienti, vaccini di nuova generazione, una genomica che passa dal sequenziamento alla terapia, protesi e impianti che restituiscono capacità perdute. La rubrica segue le sperimentazioni cliniche concluse, le autorizzazioni all’immissione in commercio, le adozioni ospedaliere — il momento in cui una tecnologia smette di essere una pubblicazione per diventare una cura.
I numeri comandano: coorti, tassi di rilevamento, mortalità evitata, costi. Copriamo volentieri i sistemi sanitari che adottano su larga scala — l’India, il Brasile, il Sud-est asiatico — perché le tecnologie frugali si mettono spesso alla prova lì prima di arrivare altrove. Ogni articolo si appoggia alla sperimentazione, all’autorizzazione o allo studio che lo fonda, e li cita.
- Johnson & Johnson’s Imaavy is cleared for patients aged 12 and older with warm autoimmune hemolytic anemia.
The TEAMSS initiative worked with 160 clinicians at 27 pediatric clinics across 18 states.
The circuit links the amygdala and prefrontal cortex, two regions involved in emotion and decision-making.
Northwestern researchers tested more than 1,900 NAT10 variants in one proliferation assay.
L-32 targets PTPN22, a protein that restrains immune activity.
The system estimates both tumor volume and where its segmentation may be wrong.
Penn State researchers tested 12 guinea fowl, six of which carried weights equal to 4% of body weight during growth.
At one year, 23.6% of thrombectomy patients were functionally independent, versus 6.8% receiving medical care.
The cells carry CHL1, a gene not normally found on healthy-lung fibroblasts.
The combination pushed tumor-cell DNA damage beyond repair, triggering programmed cell death.
Researchers at National Taiwan University built the first spatial map of ovarian clear cell carcinoma.
The changes differ between infectious and noninfectious forms of Trypanosoma cruzi.
The STAR-TREC phase 2/3 trial enrolled more than 500 patients across five European countries.
- The regimen alternated 24 hours of fasting with 24 hours of unrestricted feeding for 38 days.
Peter Mac researchers identified four proteins pancreatic cancer cells rely on to grow and survive.
Georgia State's method aligns brain timescales before comparing network signal strength.
A Cornell team activated macrophages after targeted therapy to recruit immune cells against resistant melanoma cells.
The recordings came from 23 patients during deep brain stimulation surgery.